Coronary revascularization for myocardial ischemia.

摘要

The survival of patients with acute myocardial infarction (MI) has improved considerably during the past 15 years with the advent of thrombolytic therapy, including better utilization of anticoagulants, aspirin, and cardioprotective drugs such as β-blockers and ACE inhibitors. Despite this improvement, mortality rates after MI continue to demonstrate an early rise during the first 3 months, with a slower but steady increase afterward.1 The principal cardiac factors influencing survival after MI are the size of the infarct and its impact on left ventricular (LV) function, the presence of residual ischemia, recurrent infarction, and ventricular arrhythmias. These factors can coexist in the same patient and exert a negative synergistic effect on survival.